Course title: 2019 Updates on Safe Prescribing for Pain and Use of the Utah Controlled Substance Database

Description: This two-hour course will fulfill your licensing requirement for the Division of Professional Licensing (DOPL) and give updates on best practices for safe and effective pain medication prescribing for all types of dental providers. The course covers how to select the most appropriate pain medication therapy based on specific patient data, appropriate opioid prescribing practices for dental patients, and updates on the appropriate use of the Utah Controlled Substance Database in your practice.

Objectives:
This course will ensure attendee understanding of
- the epidemiology of opioid abuse
- the pathophysiology of pain in the dental patient
- evidence-based options for pain therapy, and
- current laws governing the use of the Utah Controlled Substance Database

The session will include case-based learning and brief demonstration of new features of the Utah Controlled Substance Database.

Detailed agenda:
1) Introduction and Welcome: 5 minutes
   a) Disclosures

2) Epidemiology of Opioid Abuse  Susan Watson  5 minutes

3) Pathophysiology of Pain      Danielle Gundrum  10 minutes
   a) Define pain
   b) Review the process of nociception
   c) Differentiate between acute and chronic pain scenarios
   d) Identify pain assessment techniques and tools

4) Pharmacology                   Tressa McMorris  10 minutes
   a) Differentiate between pharmacologic medication classes and their mechanism of action
   b) Understand common side effect profiles of opioid and non-opioid pain medications

5) Options for therapy           Tressa McMorris  20 minutes
   a) Summarize contraindications, warnings, and precautions of pharmacologic therapy options
   b) Select the most appropriate pain medication therapy based on specific patient data
   c) Explain appropriate opioid prescribing practices for a dental pain patient
6) Break 10 minutes

7) The New and Improved Utah’s Controlled Substance Database

   Melanie Wallentine 15 minutes

   a) brief demonstration of new features of the CSD
   b) Q and A

8) Case Studies Andrew Drollinger/David Anderson 35 minutes

   a) Contraindications/Red Flags for opioid prescriptions/High Risk patients
      (incorporate CSD as part of case)
   b) GI disease/Kidney disease/Heart disease
   c) Previous History of Substance Use (incorporate CSD as part of case)
   d) Age of client

9) Post-test >90%/Evaluation 5 minutes